

**Registered Office**

Pushpak, 1<sup>st</sup> Floor  
Panchvati Circle  
Motilal Hirabhai Road  
Ahmedabad 380006  
Gujarat, India  
**Phone** +91 79 264 45106

**Factory**

Village Merda-Adraj  
Taluka Kadi  
District Mehsana  
Gujarat 382721, India  
**Phone** +91 2764 285 502  
+91 2764 285 453

**Email** mail@hester.in  
[www.hester.in](http://www.hester.in)

**CIN** L99999GJ1987PLC022333

**10 May 2024**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai 400 051

**Scrp Code: 524669****Symbol: HESTERBIO****Dear Sir/ Madam:**

**Subject: Outcome of Board Meeting and submission of Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2024**

This is with reference to our letter dated 2 May 2024 intimating the date of the Board Meeting for consideration of the audited standalone and consolidated financial results for the quarter and year ended 31 March 2024 and to consider the declaration of dividend, if any, on the equity shares of the Company for the financial year 2023-24.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the followings:

- 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2024, as recommended by Audit Committee and the Audited Standalone and Consolidated Financial Statements for the year ended 31 March 2024.

Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended time to time), we hereby state that the Statutory Auditors of the Company, Chandulal M. Shah & Co., Chartered Accountants (FRN: 101698W) have issued an Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31 March 2024.

- 2) Recommended dividend of ₹ 6 (Six) per equity share of ₹ 10 each (60%) for the financial year 2023-24, subject to approval of members at the ensuing Annual General Meeting.
- 3) The Board, on recommendation of Nomination and Remuneration Committee, subject to the approval of Shareholder and such other approvals as may be required, approved the revision in remuneration of Ms. Priya Gandhi, Executive Director (Whole-time) of the Company with effect from September 2024, for the remaining period of current tenure.

We attach herewith:

- 1) The approved audited standalone and consolidated financial results and auditors' reports
- 2) A Press Release issued in this regard

We will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 10:32 a.m. (IST) and concluded at 12:09 p.m. (IST).



**HESTER**

**Hester Biosciences Limited**

**Registered Office**

Pushpak, 1<sup>st</sup> Floor  
Panchvati Circle  
Motilal Hirabhai Road  
Ahmedabad 380006  
Gujarat, India

**Phone** +91 79 264 45106

**Factory**

Village Merda-Adraj  
Taluka Kadi  
District Mehsana  
Gujarat 382721, India

**Phone** +91 2764 285 502  
+91 2764 285 453

**Email** mail@hester.in

[www.hester.in](http://www.hester.in)

**CIN** L99999GJ1987PLC022333

We shall inform you in due course the date on which the Company will hold its Annual General Meeting for the year ended 31 March 2024 and the date from which dividend, if approved by the shareholders, will be paid or warrants thereof dispatched to the shareholders.

You are requested to take the above information on your record.

**Sincerely**  
**For Hester Biosciences Limited**

**Vinod Mali**  
**Company Secretary & Compliance Officer**

Enclosure: As above